pipette
ENEnglish

A Biomarker-Integrated Day 7 Response Reliably Predicts Outcomes in Minnesota Standard Risk Acute GVHD

I. E. Louloudis, A. Alousi, T. Wang, M. Diniz, D. Weber, F. Ayuk, H. Choe, I. Vasova, Y.-B. Chen, M. Qayed, R. Nakamura, H. Alkhateeb, A. M. Etra, M. Wolfl, R. Reshef, E. Hexner, C. L. Kitko, P. Aguayo-Hiraldo, M. Ali, P. Bader, C. Chanswangphuwana, M. Eder, S. Kraus, M. L. MacMillan, J. Magenau, F. V. Michelis, T. Olson, J. Pidala, P. Reddy, M. Stelljes, R. Zeiser, Y. Akahoshi, J. Baez, G. Eng, S. Gleich, N. Katsivelos, G. Morales, T. Sebastian, N. Spyrou, R. Young, W. J. Hogan, J. L. M. Ferrara, J. E. Levine

PreprintUso en el mundo real

En palabras de los autores

Acute graft-versus-host disease (GVHD) response is conventionally assessed 28 days after treatment initiation, although treatment escalation often occurs earlier. In Minnesota standard risk acute GVHD, day 7 clinical response alone provides limited prognostic discrimination because many patients without early improvement subsequently respond without additional therapy. We hypothesized that incorporating serum GVHD biomarkers into a day 7 response assessment would improve early prognostic stratification. We studied 790 patients with Minnesota standard risk GVHD treated with systemic therapy. A MAGIC observational cohort was randomly divided into training (n=294) and validation (n=308) cohorts, and an independent interventional trial cohort (n=188) served as external validation. A classification and regression tree integrated day 7 clinical response with Ann Arbor biomarker scores to predict 6-month non-relapse mortality (NRM). The integrated model reclassified approximately 20% of patients, identifying clinical non-responders with low-risk biomarkers who had favorable outcomes and clinical responders with high-risk biomarkers who remained at increased risk. In the training cohort, the integrated model improved prediction of 6-month NRM compared with day 7 clinical response alone (AUC, 0.76 vs 0.63; P=.002) and performed comparably to conventional day 28 clinical response (AUC, 0.70). These findings were reproduced in both validation cohorts. Among day 7 clinical non-responders, biomarker status identified biologically favorable slow responders and also stratified outcomes among patients who received second-line therapy. A biomarker-integrated day 7 response assessment improves early prognostic stratification in Minnesota standard risk acute GVHD and may provide an earlier, more objective endpoint for clinical decision-making and future therapeutic trials.

Resultado principalEl resumen no menciona limitaciones.

Apareció: viernes, 30 de octubre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.28.26366649